List of Excipients in Branded Drug NYSTATIN AND TRIAMCINOLONE

« Back to Dashboard

Generic Drugs Containing NYSTATIN AND TRIAMCINOLONE

Company	Ingredient	NDC	Excipient
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	ALUMINUM HYDROXIDE
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	CETEARETH-15
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	GLYCERYL MONOSTEARATE
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	METHYLPARABEN
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	PETROLATUM
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	POLYSORBATE 60
STAT RX LLC USA	nystatin and triamcinolone acetonide	16590-173	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in NYSTATIN AND TRIAMCINOLONE?

# Of NDCs	Excipient
2	ALUMINUM HYDROXIDE
2	CETEARETH-15
1	DIMETHICONE
2	GLYCERYL MONOSTEARATE
2	METHYLPARABEN
1	MINERAL OIL
3	PETROLATUM

Nystatin and Triamcinolone Excipient Strategy and Commercial Opportunities

Last updated: October 29, 2026

Nystatin and triamcinolone acetonide is an established topical prescription combination for cutaneous candidiasis with inflammatory symptoms. The standard strength is nystatin 100,000 units/g with triamcinolone acetonide 0.1% in cream or ointment. Its commercial opportunity is primarily in differentiated topical vehicles, packaging, tolerability, manufacturing efficiency, and targeted generic substitution rather than new-compound exclusivity.

The product has limited patent-based protection because the active ingredients and combination have been marketed for decades. Competitive advantage depends on formulation performance, regulatory execution, supply reliability, and distribution.

What is nystatin and triamcinolone used for?

Nystatin and triamcinolone treats fungal skin infections caused by Candida species when inflammation, erythema, or pruritus is present. Nystatin provides antifungal activity. Triamcinolone acetonide is a medium-potency topical corticosteroid that reduces inflammation and itching.

The combination is intended for external dermatologic use. FDA labeling generally limits treatment duration and warns against prolonged or extensive use because topical corticosteroids can cause skin atrophy, systemic absorption, hypothalamic-pituitary-adrenal axis suppression, and other adverse effects. The product should not be used ophthalmically and is not appropriate for every dermatologic rash that appears inflamed.[1]

What are the marketed strengths and dosage forms?

Dosage form	Nystatin strength	Triamcinolone acetonide strength	Typical commercial vehicle
Cream	100,000 units/g	0.1% w/w	Emulsion cream
Ointment	100,000 units/g	0.1% w/w	Hydrocarbon-based ointment

The former Mycolog-II product established the combination’s commercial reference profile. Multiple generic manufacturers market products under abbreviated new drug applications, commonly abbreviated ANDAs. Product availability, package sizes, inactive ingredients, and labeling can vary by manufacturer.[1][2]

What excipients are used in nystatin and triamcinolone products?

The excipient system depends on whether the product is a cream or ointment and on the manufacturer’s formulation. Public FDA labeling shows that cream formulations commonly use water, emulsifiers, fatty alcohols, humectants, preservatives, and pH-adjusting agents. Ointments typically use petrolatum and mineral-oil-based excipients.

Typical cream excipient functions

Excipient category	Formulation function	Commercial relevance
Purified water	Continuous phase in an oil-in-water emulsion	Supports spreadability and washability
Fatty alcohols such as cetyl or stearyl alcohol	Emulsion stabilization, viscosity, skin feel	Affects greasiness and sensory acceptance
Mineral oil or other emollients	Occlusion and moisturization	Can improve retention but increase tack
Propylene glycol or other humectants	Moisture retention and solvent function	May improve texture but can irritate sensitive skin
Polysorbates or nonionic emulsifiers	Emulsion stabilization	Can affect drug release and compatibility
Preservatives	Microbial control in water-containing products	Creates sensitization and regulatory considerations
Buffers or phosphate salts	pH control	Helps maintain stability and product consistency
Chelating agents	Control trace-metal effects	May support preservative performance and stability

These categories describe common formulation functions, not a universal composition. The inactive ingredient list must be assessed product by product using the relevant FDA label or DailyMed entry.[2]

Typical ointment excipient functions

Ointments commonly rely on white petrolatum, mineral oil, or related hydrocarbon materials. These excipients provide occlusion, reduce transepidermal water loss, and can enhance residence time on the skin. Their disadvantages are greasiness, poor washability, and lower cosmetic acceptability for daytime or intertriginous use.

Ointments can be commercially attractive for dry, fissured, or highly inflamed lesions. Creams are generally better positioned for broad outpatient use because they spread more easily and are more acceptable to patients who do not want a heavy residue.

How should an excipient strategy be designed for this combination?

An effective excipient strategy should preserve antifungal delivery while controlling corticosteroid exposure and improving patient adherence. The two active ingredients create different technical requirements.

Nystatin is a polyene antifungal with limited aqueous solubility and sensitivity to formulation conditions. Triamcinolone acetonide is a potent synthetic corticosteroid with low water solubility. The formulation therefore must control solid-state dispersion, particle size, phase distribution, content uniformity, release, and skin deposition.

Which excipient attributes matter most?

The primary formulation targets are:

1. Uniform distribution of both active ingredients.
2. Acceptable physical and chemical stability.
3. Reproducible viscosity and spreadability.
4. Controlled release and skin deposition.
5. Low irritation and sensitization potential.
6. Microbiological robustness.
7. Compatibility with tubes, pumps, or other packaging.
8. Efficient scale-up and filling.

The most important development risk is assuming that a visually uniform cream has equivalent performance. For a combination product, each active may partition differently between the oil and aqueous phases. Changes in emulsifier type, solvent level, particle size, or viscosity can alter release and deposition even when assay remains within specification.

How can the cream vehicle be differentiated?

A commercial cream platform can target the following attributes:

• Lower greasiness than conventional generic creams.
• Faster rub-in and reduced residue.
• Improved washability.
• Reduced stinging on compromised skin.
• Lower preservative burden.
• Better compatibility with sensitive-skin use.
• Improved dose consistency through a metered pump.
• Longer physical stability under temperature excursions.

A water-washable oil-in-water emulsion is likely to have the broadest consumer acceptance. The tradeoff is greater microbiological risk and more complex preservative validation than with an anhydrous ointment.

How can the ointment vehicle be differentiated?

An ointment platform can target:

• Enhanced occlusion for dry lesions.
• Reduced tackiness.
• Improved extrusion from the tube.
• Lower oil migration into clothing.
• Better low-temperature performance.
• Reduced graininess or phase separation.
• Unit-dose or controlled-dose delivery.

The opportunity is strongest where the clinical need favors occlusion but patients reject conventional petrolatum-heavy products.

What formulation patents protect nystatin and triamcinolone?

The original combination and standard cream and ointment presentations are mature products. Commercially relevant protection is more likely to arise from formulation-specific patents, delivery systems, manufacturing processes, or packaging than from the active ingredients themselves.

Protection category	Likely commercial importance	Assessment
Nystatin composition of matter	Very low	Long-established active ingredient
Triamcinolone acetonide composition of matter	Very low	Long-established corticosteroid
Fixed-dose combination	Low	Legacy combination with long market history
Conventional cream formulation	Low to moderate	Generic competition and mature technology
Conventional ointment formulation	Low to moderate	Limited differentiation unless performance is novel
Specialized delivery system	Moderate to high	Potential basis for an improved product
Preservative-free or low-preservative system	Moderate	Requires robust microbiological and stability data
Metered-dose packaging	Moderate	May support adherence and dose control
Manufacturing process	Moderate	Can protect quality, yield, or stability improvements
Method-of-use claims	Limited	Subject to prior-art and obviousness risk

A current patent search and Orange Book review are required before relying on any specific patent number, expiration date, or litigation conclusion. No patent number should be treated as commercially controlling without confirmation in the FDA Orange Book, USPTO records, and relevant court dockets.

What is the Orange Book status of nystatin and triamcinolone?

Nystatin and triamcinolone products are prescription topical products generally supplied through ANDA-based generic competition. The Orange Book is the relevant FDA database for approved drug products and listed patents, but topical products may have limited or no currently meaningful listed-patent protection compared with newer branded medicines.[3]

The principal regulatory questions are:

• Whether the reference product has an active listing.
• Whether any patents are listed against the relevant dosage form.
• Whether the proposed product can rely on ANDA therapeutic equivalence.
• Whether a formulation change requires a different FDA pathway.
• Whether labeling, inactive ingredients, and manufacturing changes remain within the reference-product framework.

If a listed patent exists, a Paragraph IV certification could trigger Hatch-Waxman litigation. If no relevant listed patent exists, a generic applicant usually faces a lower patent barrier, although regulatory, manufacturing, and supply risks remain.

When does nystatin and triamcinolone lose exclusivity?

The active ingredients lost practical market exclusivity many years ago. The product’s commercial exclusivity is therefore based on regulatory approval, manufacturer supply, branding, distribution, and any surviving formulation or process rights.

Exclusivity element	Status
New chemical entity exclusivity	Expired or inapplicable
Original combination exclusivity	Expired
Conventional formulation exclusivity	Generally expired or weak
FDA generic pathway	Available, subject to reference-product and ANDA requirements
Orphan-drug exclusivity	Not applicable to the standard product
Biosimilar exclusivity	Not applicable
Potential device or packaging protection	Product-specific
Potential formulation patent protection	Product-specific and requires verification

No biosimilar pathway applies because nystatin and triamcinolone are small-molecule active ingredients rather than biologics. The competitive pathway is generic drug approval, not biosimilar interchangeability.

Which companies are challenging nystatin and triamcinolone?

Generic competition has historically included multiple ANDA sponsors and contract manufacturers. The competitive set can change as approvals are withdrawn, transferred, discontinued, or reintroduced. FDA’s Drugs@FDA, Orange Book, and DailyMed records are the controlling sources for current approval status and label-specific manufacturer information.[2][3]

Competition is likely to include:

• Large generic dermatology suppliers.
• Private-label distributors.
• Contract development and manufacturing organizations.
• Regional generic companies.
• Manufacturers offering cream and ointment alternatives.
• Specialty pharmaceutical companies with differentiated topical delivery systems.

The market is fragmented enough that reliability and customer service can influence share. Pharmacies and group purchasing organizations often prioritize price, availability, and substitution status over minor vehicle differences.

What commercial opportunities exist for improved excipients?

Preservative-reduced and sensitive-skin formulations

A reduced-preservative or preservative-free cream could target patients who experience irritation from conventional vehicles. This strategy requires strong container-closure protection, microbial challenge testing, manufacturing controls, and a clear rationale for the selected packaging.

An airless pump or other low-exposure package could reduce repeated environmental contamination. The package may also enable more consistent dosing than an open tube, but it increases component cost and device-validation requirements.

Better cosmetic acceptability

A non-greasy, rapidly absorbed cream has the strongest mass-market opportunity. Patient adherence may decline when a product feels oily, stains clothing, or leaves visible residue. Excipient selection can improve sensory properties without changing the active strengths.

The commercial claim must remain within the approved labeling and substantiated product-performance data. Cosmetic improvements alone do not create clinical superiority.

Low-cost, high-reliability generics

The largest near-term opportunity may be operational rather than technical. A manufacturer can compete through:

• Stable supply of both cream and ointment.
• Dual-source raw materials.
• Efficient tube-filling operations.
• Reduced batch failure rates.
• Long shelf life.
• Reliable wholesaler inventory.
• Competitive contract pricing.

For a mature generic, a small improvement in manufacturing yield or packaging throughput can have more value than a complex reformulation.

Pediatric and intertriginous-use positioning

The product’s steroid component limits broad or prolonged use, especially in children and thin-skin areas. A commercial strategy can focus on accurate dosing, smaller package sizes, and clinician education rather than stronger steroid exposure.

Any pediatric positioning must remain consistent with the FDA label. A new vehicle does not remove corticosteroid-related safety limitations.

International opportunity

Regulatory strategies differ by jurisdiction. The United States uses FDA pathways and Orange Book standards. Europe, Canada, Australia, and emerging markets may apply different requirements for generic topical equivalence, local reference products, and excipient acceptability.

Geographic expansion can be attractive where Candida skin infections are commonly treated and generic topical supply is fragmented. The main barriers are local registration, reference-product selection, labeling translation, pharmacopoeial requirements, and distribution economics.

What manufacturing and intellectual-property barriers exist?

The key manufacturing barriers are technical reproducibility and microbial control.

For creams, critical process variables include emulsification temperature, shear, cooling profile, order of addition, active dispersion, deaeration, and filling temperature. For ointments, particle dispersion, heating, cooling, and filling behavior are central.

The main IP barriers can include:

• Patented emulsifier systems.
• Novel particle-size or micronization approaches.
• Controlled-release topical platforms.
• Airless or metered packaging.
• Manufacturing processes that improve stability.
• Combination products with additional active ingredients.
• Formulations designed for specific deposition profiles.

A formulation patent has stronger commercial value when it covers a measurable product attribute that is difficult to design around. Broad claims directed only to familiar excipient combinations may face validity and obviousness challenges.

What patent litigation affects nystatin and triamcinolone?

No major current patent dispute can be identified from the information provided. The product is a mature generic combination, and litigation risk is more likely to arise from a newly developed formulation, delivery device, or manufacturing process than from the conventional cream or ointment.

A Paragraph IV challenge would matter only if an applicant targets an approved product with an active Orange Book-listed patent. A patent owner could sue within the Hatch-Waxman framework, potentially triggering a regulatory stay. Without an active listed patent, commercial entry is more likely to turn on ANDA approval, therapeutic-equivalence designation, manufacturing readiness, and market access.

How does nystatin and triamcinolone compare with competing topical products?

Product type	Antifungal	Steroid	Main advantage	Main limitation
Nystatin alone	Yes	No	Avoids steroid exposure	Less useful when inflammation is prominent
Triamcinolone alone	No	Yes	Controls inflammation	Does not treat Candida
Nystatin plus triamcinolone	Yes	Yes	Addresses fungal infection and inflammation	Steroid safety limits duration and site
Azole antifungal alone	Yes	No	Broad antifungal use	Does not directly control inflammation
Antifungal plus low-potency steroid	Yes	Yes	May reduce steroid exposure	May have different efficacy and labeling
Barrier or zinc-based product	No	No	Supports moisture and skin protection	Not an antifungal treatment

The combination competes against separate prescriptions and over-the-counter antifungal products. Its value is highest when clinicians want one prescription product for confirmed or strongly suspected Candida infection with inflammatory symptoms.

Key Takeaways

• Nystatin and triamcinolone is a mature prescription topical combination available mainly as cream and ointment.
• The standard strength is nystatin 100,000 units/g with triamcinolone acetonide 0.1%.
• Conventional active-ingredient and combination exclusivity has expired.
• Biosimilar risk does not apply; competition proceeds through generic drug pathways.
• Excipient opportunities include improved spreadability, lower greasiness, reduced preservative burden, improved dose control, and better packaging.
• Creams offer the broadest commercial opportunity because of washability and cosmetic acceptance.
• Ointments remain relevant for dry or highly inflamed lesions that benefit from occlusion.
• Patent value is more likely to come from specialized vehicles, devices, or manufacturing processes than from the legacy formulation.
• Current Orange Book listings, ANDA approvals, patent status, and litigation should be verified product by product before launch or licensing decisions.
• Manufacturing reliability, microbiological control, packaging performance, and supply continuity are major sources of commercial advantage.

Frequently Asked Questions

Is nystatin and triamcinolone a combination drug or two separate medicines?

It is a fixed-dose topical combination containing the antifungal nystatin and the corticosteroid triamcinolone acetonide.

Can a preservative-free nystatin and triamcinolone cream be developed?

Yes, but the formulation would require appropriate container-closure protection, microbial challenge testing, stability data, and a regulatory assessment of whether the product remains suitable for the intended approval pathway.

Does a new excipient automatically create a new patent opportunity?

No. Patentability depends on novelty, non-obviousness, claim scope, and supporting technical evidence. A new excipient is more defensible when it produces an unexpected stability, delivery, tolerability, or manufacturing result.

Is nystatin and triamcinolone interchangeable with an antifungal cream?

Not automatically. The combination includes a corticosteroid and has different labeling, risks, and use restrictions from antifungal-only products.

What is the most attractive commercial formulation opportunity?

A cosmetically acceptable, low-irritation cream with reliable stability, efficient packaging, and competitive manufacturing economics is the strongest broad-market opportunity. A specialized ointment can support a narrower strategy focused on occlusion and severe dryness.

References

1. U.S. Food and Drug Administration. (n.d.). Nystatin and triamcinolone acetonide cream and ointment prescribing information. FDA-approved product labeling.

2. National Library of Medicine. (n.d.). DailyMed: Nystatin and triamcinolone acetonide topical products. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm